MimEX™ Tissue Model Systems

Friday, March 02, 2018 - 13:29

This video provides an overview of MimEX™ Tissue Model Systems, a next-generation 3-dimensional (3-D) cell culture platform for the generation of ex vivo epithelial-derived organ tissue. Learn the basics about how to incorporate this model system into your research, including how it compares to existing 3-D cell culture and organoid models. MimEX™ Tissue Model Systems harnesses the unique characteristics of adult ground-state epithelial stem cells to generate ex vivo organ tissue that recapitulates native cytoarchitecture and mimics physiological attributes of the desired organ. Consisting of optimized media and reagents, MimEX™ Tissue Model Systems provides an alternative to current 3-D cell culture modes, such as organoids, with the added benefit of better tissue access, control of tissue variability, and regional and disease tissue specificity.

Click here to learn more about MimEX™ Tissue Model Systems


Portions of this product are covered by a license to intellectual property owned by, or licensed to, Multiclonal Therapeutics, Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right under these intellectual property rights to use this product for research purposes only. The purchase of this product does not include any right to use this product or components of this product for resale, for drug discovery intended for commercial gain, for the generation of cells or tissues intended for transplantation in human patients, or for any other commercial purposes, including without limitation, provision of services to a third party, generation of commercial databases, or as a diagnostic or therapeutic. Multiclonal Therapeutics, Inc., reserves all other rights under these rights. For information on purchasing a license to the intellectual property for uses other than in conjunction with this product or to use this product for purposes other than research, please contact Multiclonal Therapeutics, Inc. at licensing@multiclonaltherpaeutics.com.

Blog Categories: